LivaNova Reports Strong Q1 Results, Raises Full-Year Guidance, and Secures Key FDA Approval for Sleep Apnea Device

summarizeSummary

LivaNova PLC reported strong Q1 2026 financial results, raised its full-year revenue and adjusted EPS guidance, and received FDA approval for its aura6000™ System for obstructive sleep apnea.

check_boxKey Events

• Strong First-Quarter 2026 Financial Performance

  LivaNova reported Q1 2026 revenue of $362.3 million, an increase of 14.3% on a reported basis and 11.1% on a constant-currency basis. Adjusted diluted earnings per share rose to $0.98 from $0.88 in the prior-year period.

• Full-Year 2026 Guidance Raised

  The company raised its full-year 2026 constant-currency revenue growth guidance by 100 basis points to a range of 7.0% to 8.0%. Adjusted diluted EPS guidance was also increased by $0.05 at the midpoint, now expected to be between $4.20 and $4.30.

• FDA Approval for aura6000™ System

  LivaNova received U.S. FDA premarket approval for its aura6000™ System to treat moderate to severe obstructive sleep apnea. This device is noted as the first and only hypoglossal nerve stimulation system approved without certain contraindications, opening a new high-growth market.

auto_awesomeAnalysis

LivaNova PLC delivered robust first-quarter results, exceeding expectations with double-digit revenue growth and improved adjusted earnings per share. The company's decision to raise its full-year 2026 revenue and adjusted EPS guidance signals strong operational momentum and a positive outlook for the remainder of the year. Critically, the FDA premarket approval for the aura6000™ System for obstructive sleep apnea marks a significant product development milestone, positioning LivaNova to enter a high-growth, high-margin market with a differentiated technology. This combination of strong financial performance, an upgraded outlook, and a major regulatory approval provides a compelling positive catalyst for the company's trajectory.